Mast Therapeutics (MSTX) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.
Mast Therapeutics (MSTX) : The highest level Mast Therapeutics (MSTX) is projected to reach is $5 for the short term and the lowest estimate is at $1. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $2.67 and the possibility the share price can swing is $2.08.
For the current week, the company shares have a recommendation consensus of Buy.
Mast Therapeutics (NYSEMKT:MSTX): stock was range-bound between the intraday low of $0.611 and the intraday high of $0.6773 after having opened at $0.64 on Wednesdays session. The stock finally closed in the red at $0.64, a loss of -0.65%. The stock remained in the red for the whole trading day. The total traded volume was 8,102,819 shares. The stock failed to cross $0.6773 in Wednesdays trading. The stocks closing price on Thursday was $0.651.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).